Ex-Axovant COO Marion McCourt lands at Regeneron; GT Biopharma elevates Shawn Cross to CEO in exec reshuffle
→ While our eyes were fixed on CEO David Hung’s departure from struggling Axovant, COO Marion McCourt also quietly jumped ship — to Regeneron $REGN. The company announced Monday (the same day McCourt’s resignation from Axovant was made public) that it has appointed her as SVP and head of commercial. The appointment filled a vacancy left by Robert Terifay, who resigned last month in the middle of a medical leave and plans to retire in July. A seasoned exec with footprints at AstraZeneca, Amgen and Medivation, McCourt will lead the commercialization for both approved medicines and develop-stage pipeline.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.